APOB and amyotrophic lateral sclerosis: Using genetic proxies for lipid-lowering therapies targeting four individual genes, this study suggests that reducing LDL-c levels through targeting of APOB (a genetic proxy for Mipomersen treatment) could reduce the risk of ALS and FTD.